Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. While no therapies are approved for AA, topical corticosteroids and topical contact allergens are commonly prescribed; JAK inhibitors (Pfizer’s Xeljanz, Eli Lilly’s Olumiant, Incyte’s Jakafi) may also be prescribed, albeit infrequently. This claims data analysis offers insight into the current treatment landscape and physicians’ prescribing practices in AA.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Markets covered: United States
Key companies: Amgen, Eli Lilly, Horizon Pharma, Incyte, Janssen, Novartis, Pfizer, Regeneron, Sanofi
Key drugs: Anthralin, corticosteroids, Elidel (1% cream), finasteride, Jakafi, Olumiant, tacrolimus (topical), Xeljanz